Cutaneous neuroendocrine carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- Cutaneous neuroendocrine carcinoma is a primary cutaneous cancer arising from a subset of skin neuroendocrine cells (Merkel cells, giving the name Merkel cell carcinoma (MCC)).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Cutaneous neuroendocrine carcinoma
- Therapeutic area
- Oncology
- cutaneous neuroendocrine carcinoma
- MCC
- Merkel Cell Carcinoma
- Merkel cell cancer
- Merkel cell carcinoma
- Merkel cell tumor
- Merkel cell tumour
- carcinoma of Merkel cell
- cutaneous APUDoma
- cutaneous neuroendocrine carcinoma
- neuroendocrine carcinoma of skin
- neuroendocrine carcinoma of the skin
- neuroendocrine skin carcinoma
- trabecular cancer
- trabecular skin carcinoma
- Merkle tumors
- Merkle tumours
- carcinoma, Merkel cell
- Severity
- Severe
- Acquired
- Developmental
- Dermatology
- Endocrinology
- Neurology
- Oncology
- MONDO ID
- MONDO:0019210
- Parent condition
- MONDO:0002120
Related records
Broader conditions (35)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Dermis disorder
- Dermis tumor
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Disorder of development or morphogenesis
- Endocrine gland neoplasm
- Endocrine system disorder
- Epithelial neoplasm
- Epithelial skin neoplasm
- Human disease
- Integumentary system cancer
- Integumentary system disorder
- Malignant dermis tumor
- Malignant endocrine neoplasm
Trials (150)
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
- A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
- A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
- A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- A Study of CRD3874-SI in People With Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
- A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
- A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
- A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Approved drugs (2)
Drugs in development (35)
- Aldesleukin Phase 1
- Bevacizumab Phase 1
- Capecitabine Phase 1
- Carboplatin Phase 2
- Cemiplimab Phase 2
- Cisplatin Phase 2
- Cyclophosphamide Phase 2
- Domatinostat Phase 2
- Etoposide Phase 2
- F16IL2 Phase 2
- Fluorouracil Phase 2
- Imatinib mesylate Phase 2
- Interferon beta Phase 1
- Ipilimumab Phase 2
- Irinotecan hydrochloride Phase 2
- Lanreotide Phase 2
- Lenvatinib Phase 2
- Leucovorin calcium Phase 1
- Lutetium oxodotreotide LU-177 Phase 2
- Methotrexate Phase 2